Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 226 Published: May 31, 2022 Report Code: GDGMDHC22186IDB

The Women Infertility pipeline market report provides a comprehensive overview of the therapeutics under development for Women Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects.

Women Infertility Pipeline Drugs Market by Key Targets

In the Women Infertility pipeline drugs market, the key targets are Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype.

Key Targets in the Women Infertility Pipeline Drugs Market

Key Targets in the Women Infertility Pipeline Drugs Market

For more target insights, download a free report sample

Key MoA in the Women Infertility Pipeline Drugs Market

Follicle Stimulating Hormone Receptor Agonist has the highest share in the Women Infertility Pipeline Drugs Market. The other key mechanisms of action are Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist.

Women Infertility Pipeline Drugs Market Analysis, by MoA

Women Infertility Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free sample report

Women Infertility Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Women Infertility pipeline drug market are oral, subcutaneous, intravenous, intramuscular, vaginal, parenteral, injection, intraarterial, intracavitary, and intrauterine. Oral has the maximum number of pipeline products.

Women Infertility Pipeline Drugs Market Analysis, by RoA

Women Infertility Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Women Infertility Pipeline Drugs Market

The key molecule types in the Women Infertility pipeline drugs market are Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy. Small molecule has the maximum number of pipeline products.

Women Infertility Pipeline Drugs Market, by Molecule Types

Women Infertility Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Women Infertility Pipeline Drugs Market

Some of the major companies in the Women Infertility pipeline drugs market are Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd.

Women Infertility Pipeline Drugs Market, by Major Companies

Women Infertility Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Women Infertility Pipeline Drugs Market Overview

Key Targets Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype
Key Mechanisms of Action Follicle Stimulating Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist
Key Routes of Administration Oral, Subcutaneous, Intravenous, Intramuscular, Vaginal, Parenteral, Injection, Intraarterial, Intracavitary, and Intrauterine
Key Molecule Types Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy
Major Companies Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility
  • The pipeline guide reviews pipeline therapeutics for Women Infertility by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Women Infertility therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Women Infertility therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Women Infertility

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Women Infertility
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

AlphaMab Co Ltd
Amega Biotech
Anelleo Inc
Aprilbio Co Ltd
Aptorum Group Ltd
ASKA Pharmaceutical Holdings Co Ltd
Bayer AG
BCI Pharma SA
Beijing FuKangren Bio-pharm Tech Co Ltd
Beijing SL Pharmaceutical Co Ltd
Bharat Serums And Vaccines Ltd
Bol Pharma
Bopin (Shanghai) Biomedical Technology Co Ltd
Chugai Pharmaceutical Co Ltd
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Egret Therapeutics Inc
Eikonoklastes Therapeutics Inc
ElexoPharm GmbH
Endomet Biosciences Inc
Enteris BioPharma Inc
Eurofarma Laboratorios SA
Evestra Inc
Evotec SE
Ferring International Center SA
Ferring Pharmaceuticals Inc
Forendo Pharma Ltd
GeneScience Pharmaceuticals Co Ltd
Genome & Co
Glycotope GmbH
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hope Medicine Inc
Igenomix SL
Igyxos SA
Immunitor Inc
Insud Pharma
Ironwood Pharmaceuticals Inc
Isifer AB
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Medibiofarma SL
Mithra Pharmaceuticals SA
Mitsubishi Tanabe Pharma Corp
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Neuromagen Pharma Ltd
Nippon Shinyaku Co Ltd
NutriBand Inc
ObsEva SA
Oxolife SL
Pangen Biotech Inc
Park of Active Molecules
Pharmasyntez
Predictive Therapeutics LLC
PregLem SA
Reven Holdings Inc
Shandong TheraWisdom Biopharma Co Ltd
Shanghai Jing Ze Biotechnology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
SYNG Pharmaceuticals Inc
Synokem Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Temple Therapeutics BV
TiumBio Co Ltd
Trophogen Inc
Unicohealth Pharma Co Ltd
ValiRx Plc
Viramal Ltd
Xbrane Biopharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Women Infertility – Overview

Women Infertility – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Women Infertility – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Women Infertility – Companies Involved in Therapeutics Development

Women Infertility – Drug Profiles

Women Infertility – Dormant Projects

Women Infertility – Discontinued Products

Women Infertility – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Women Infertility, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Women Infertility – Dormant Projects, 2022

Women Infertility – Dormant Projects, 2022 (Contd..1)

Women Infertility – Dormant Projects, 2022 (Contd..2)

Women Infertility – Dormant Projects, 2022 (Contd..3)

Women Infertility – Dormant Projects, 2022 (Contd..4)

Women Infertility – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Women Infertility, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

In the Women Infertility pipeline drugs market the key targets are Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype.

In the Women Infertility pipeline drugs market the key mechanisms of action are Follicle Stimulating Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist.

The key routes of administration in the Women Infertility pipeline drug market Oral, Subcutaneous, Intravenous, Intramuscular, Vaginal, Parenteral, Injection, Intraarterial, Intracavitary, and Intrauterine. Oral has the maximum number of pipeline products.

The key molecule types in the Women Infertility pipeline drug market are Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy.

In the Women Infertility pipeline drugs market the major companies are Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd.

$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Enquire Before Buying

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods